摘要
目的 比较奎硫平与利培酮治疗首发精神分裂症的疗效和安全性。方法 将 12 0例首发精神分裂症患者随机分为研究组 (奎硫平治疗组 ) 6 0例和对照组 (利培酮治疗组 ) 6 0例。研究组奎硫平剂量范围 10 0～ 80 0mg·d-1,对照组利培酮剂量范围1.0～ 6 .0mg·d-1,疗程均为 8w。在治疗前及治疗第 2、4、8w末采用PANSS评定临床疗效 ,治疗期间采用TESS评定药物不良反应 ,并进行比较分析。结果 奎硫平的治疗有效率为 6 8.3% ,利培酮的治疗有效率为 70 .0 % ,两组疗效无显著性差异。不良反应研究组较对照组少。其中震颤、静坐不能、肌强直等的发生率研究组显著少于对照组 (P <0 .0 1)。结论 奎硫平与利培酮治疗首发精神分裂症疗效高、耐受性好 ,两药差异不显著。
Objective To compare curative effects and safety of domestic quetiapine and risperidone in the treatment of first-episode schizophrenia. Methods 120 schizophrenics were randomly divided into quetiapine group (n=60) and risperidone group (n=60). The dosages of the quetiapine and risperidone groups were 100～800mg/d and 1.0～6.0mg/d for 8 weeks, respectively. The PANSS and TESS were used to assess the curative effects and side reactions before treatment and at the ends of the 2nd,4th and 8th week of treatment. Results Effective rates of quetiapine and risperidone were 68.3% and 70.0% respectively, which showed no significant difference. The side reactions were fewer and incidence rates of tremor, akathisia and myotonia significantly lower(P<0.01) in quetiapine group than in risperidone group. Conclusion Domestic quetiapine has similar curative effects to risperidone, fewer side effects and better tolerance, and the difference of the two drugs isn’t significant.
出处
《临床心身疾病杂志》
CAS
2004年第4期244-246,共3页
Journal of Clinical Psychosomatic Diseases
